Automated Specialty Instrumentation, Management, and Education

Automation joins physical measurement, software rules, specimen movement, and human decisions. A fast instrument can still produce an unsuitable result when the specimen, inoculum, reagent, detector, flag, interface, or review rule fails. Implementation therefore includes the technical system, the surrounding workflow, and the personnel responsible for it.

Automated microbiology systems

Automated microbiology uses several distinct instrument families. A processor can inoculate and streak plates, apply labels, move media, and capture images. An incubator can control atmosphere and temperature while imaging growth at defined intervals. A continuous-monitoring blood-culture instrument detects a change associated with microbial metabolism. Identification and antimicrobial-susceptibility systems read biochemical, growth, proteomic, or molecular responses from a prepared isolate or specimen.

Follow the specimen through the system

A positive blood-culture signal indicates that the bottle crossed the instrument’s detection rule. It does not identify the organism or prove clinical significance. The laboratory follows its positive-bottle procedure, commonly including Gram stain, subculture or validated direct testing, identification, susceptibility testing when indicated, and urgent communication.

MALDI-TOF identification compares a prepared isolate’s mass spectrum with a validated reference library. Identification quality depends on the input colony, extraction, target plate, matrix, calibration, spectrum, library content, and acceptance threshold. A high score cannot rescue a mixed culture or an organism absent from the library. The general mass-spectrometry principle is covered in Quantitative Instrument Measurement Principles.

Automated antimicrobial-susceptibility systems produce measurements that software interprets with the configured organism, drug, method, and breakpoint set. The laboratory adopts a current corrected standard, verifies the system, controls expected performance, and manages results outside the platform’s validated capability. Current U.S. CLSI interpretive criteria are in M100, 36th edition for 2026.^1,2 Microbiology modules own organism-specific identification, resistance, and reporting algorithms.

Automated hematology analyzers

Automated blood-cell analyzers combine several measurement channels. The method assigned to one reported parameter may differ between platforms.

An analyzer classifies events from the combined signals and reports counts, indices, distributions, and flags. A flag is a rule response, not a diagnosis. It may reflect an unexpected population, poor separation, a result outside an instrument limit, a specimen problem, or a known interference pattern.

Impedance cannot distinguish cells from other particles of similar pulse size. Platelet clumps, red-cell fragments, very small red cells, large platelets, nucleated red cells, and damaged leukocytes can cross channel boundaries. Cold agglutination can lower the measured red-cell count and raise MCV and calculated MCHC. Lipemia, icterus, a very high leukocyte count, or another source of turbidity can bias a photometric hemoglobin result. The actual pattern and correction depend on the analyzer.^4,10

The laboratory procedure maps each flag or implausible pattern to an action. Options include inspecting the specimen, mixing and rerunning, warming under a validated cold-agglutinin procedure, dilution, an alternate channel or method, a manual count, a blood-film review, or referral. Repeating the same unsuitable measurement without addressing its cause adds no evidence.

Liquid controls, calibration, calibration verification, background checks, carryover checks, retained-patient monitoring, moving averages, delta checks, and smear-review rules answer different questions. Moving averages and delta checks depend on patient mix and validated limits; they supplement controls and cannot replace required control procedures. The current second edition of CLSI H26 covers validation, verification, calibration, and quality assurance of automated hematology analyzers.³

For applicable nonwaived test systems, 42 CFR §493.1255 requires calibration verification at least every six months and after specified events. Those events include a complete reagent change unless the laboratory demonstrates that changing reagent lots does not affect the reportable range or controls, major preventive maintenance or critical-part replacement that may influence performance, unresolved unusual control trend or shift, and any more frequent interval in the laboratory’s established schedule. Manufacturer requirements can be more stringent.⁷

Hemostasis instrumentation

A hemostasis analyzer detects a clot, enzyme reaction, antigen, platelet response, or whole-blood viscoelastic change. Results from different principles are not interchangeable.

A random-access coagulometer can identify primary tubes, aspirate citrated plasma, add reagents, time reactions, apply calibration, display reaction curves, repeat or dilute according to rules, and transmit results. Barcode and cap-piercing features reduce selected handling errors. They do not detect every clot, fill error, wrong anticoagulant, drug effect, or optical interference. CLSI H47, third edition, provides current one-stage PT and APTT guidance for citrated platelet-poor plasma.⁵

Chromogenic anti-Xa is still interference-sensitive

A chromogenic heparin anti-Xa method measures factor Xa inhibition after the assay’s reaction steps. Residual apixaban, rivaroxaban, edoxaban, or another direct factor Xa inhibitor can add to that inhibition. A heparin-calibrated anti-Xa result may therefore appear falsely high for the heparin contribution during a transition from an oral factor Xa inhibitor. The result demonstrates anti-Xa activity and cannot separate the drugs without a validated approach. PT and APTT also have drug- and reagent-dependent sensitivity. The laboratory’s transition and monitoring protocol must account for the medication, time, renal function, assay, and available alternatives.⁶

This corrects a common misconception: an analyte-focused chromogenic endpoint can avoid some clot-detection problems and still have a clinically important molecular interferent.

Point-of-care and viscoelastic systems

Point-of-care coagulation instruments miniaturize mechanical, optical, or electrochemical detection in a cartridge or strip. Activated clotting time supports selected high-dose heparin workflows. PT/INR devices support selected vitamin K antagonist monitoring workflows. Whole blood, capillary collection, cartridge chemistry, and calibration differ from the central laboratory’s citrated-plasma method. Validation, operator controls, comparison, and a procedure for error, out-of-range, unexpected, or discordant results are required. A universal INR threshold for central-laboratory confirmation does not apply to every device or program.

Viscoelastic testing follows whole-blood clot initiation, propagation, maximum strength, and lysis. Thromboelastography commonly uses an oscillating cup with a suspended pin; rotational thromboelastometry commonly uses a rotating pin in a stationary cup. The systems use different assays and parameter names:

A parameter has meaning only with the device, activator, cartridge, time point, reference interval, and clinical algorithm used. Early trace information may appear before the full test completes. Training must cover curve quality and limitations as well as the numeric result.

Platelet-function and molecular methods

Light-transmission aggregometry follows increasing light transmission as platelets aggregate in platelet-rich plasma after agonist addition. Whole-blood impedance aggregometry follows platelet adhesion and aggregation at electrodes. Closure-time systems draw blood through a coated aperture under defined flow. Cartridge assays may use agonist-specific optical signals. Platelet count, hematocrit, collection, processing time, medications, agonist, and inherited or acquired conditions affect these methods. A closure time cannot establish or exclude von Willebrand disease or a platelet disorder by itself.

Molecular hemostasis testing uses the extraction, amplification, and sequencing principles in Flow Cytometry, Immunoassay Automation, and Molecular Methods. Clinical utility determines whether a technically detectable variant belongs in a panel. Hemostasis Disease States and Laboratory Determinations owns factor V Leiden, prothrombin G20210A, hemophilia, von Willebrand disease, platelet testing, and other disease-specific interpretation.

Selecting and implementing an automated system

Instrument selection starts with the service the laboratory must provide:

• test menu, specimen types, volume, peak arrival pattern, and required turnaround;
• measurement principles, interferences, measuring intervals, and result quality;
• hands-on time, throughput under the actual mix, reagent capacity, maintenance, and downtime;
• footprint, utilities, water, ventilation, waste, noise, ergonomics, and safety;
• open or closed consumables, lot management, storage, expiration, and supply resilience;
• interface capability, cybersecurity, data retention, middleware, autoverification, and audit trail;
• service response, remote support, staff expertise, backup method, and referral plan;
• acquisition, reagent, control, calibration, labor, service, repeat, waste, and downtime costs.

Vendor throughput under ideal loading may not predict local performance. Model the actual mix of routine, urgent, repeat, reflex, maintenance, and quality-control work. Verify the installed system before patient reporting, including performance characteristics, specimen routing, rules, flags, calculations, units, reference intervals or decision limits, critical results, interface transmission, and downtime recovery.

Cost and turnaround

A basic unit-cost estimate is:

Cost per reportable result = costs assigned to the test for a defined period ÷ reportable patient results produced in that period

Define both numerator and denominator. The numerator may include reagents, consumables, controls, calibration, proficiency testing, repeats, labor, service, depreciation or lease, middleware, utilities, waste, and allocated overhead. The denominator should follow the stated accounting rule and usually excludes controls, calibrators, failed tests, and repeats that do not create another reportable patient result. No single cost category dominates every laboratory.

Turnaround time should be measured in intervals that locate delay:

• order or collection to laboratory receipt;
• receipt to preparation or analyzer loading;
• loading to analytic completion;
• completion to review and release;
• release to required notification or clinical receipt.

A lower analytic time cannot fix a long collection, transport, queue, review, or notification delay. Workflow mapping records each handoff, decision, wait, repeat, and failure route before changing staffing or equipment.

CLIA personnel roles and responsibility

U.S. CLIA roles depend on test complexity. A laboratory director is required. Moderate-complexity testing uses a technical consultant; high-complexity testing uses a technical supervisor and general supervisor. Moderate- and high-complexity laboratories also have a clinical consultant and qualified testing personnel. One qualified individual may fill more than one role when the regulations permit it.⁷

Delegation should identify the duty, qualified designee, authority, limits, and documentation. The laboratory director remains responsible for ensuring that delegated functions are performed properly. A job title alone cannot confer a CLIA duty for which the person lacks the required qualifications.

Staffing should reflect test complexity, workload, peak timing, turnaround needs, maintenance, quality work, leave coverage, and the backup plan. A staffing model based only on average daily volume can fail during shifts with concentrated arrivals or limited supervision.

Training, competency, and continuing education

Adults bring prior experience and engage most strongly when training solves a recognizable work problem. Explain the purpose and consequence, connect the new task to existing knowledge, demonstrate the actual procedure, let the learner practice under supervision, and give specific feedback. Scenario-based problems and realistic specimens test decisions that a slide presentation cannot.⁹

CMS revised its CLIA competency brochure in May 2025. For every test performed by personnel in moderate- or high-complexity testing, competency includes six procedures:⁸

1. Direct observation of routine test performance, including patient preparation and specimen handling, processing, and testing when applicable.
2. Monitoring the recording and reporting of results.
3. Review of intermediate results or worksheets, quality-control records, proficiency-testing results, and preventive-maintenance records.
4. Direct observation of instrument performance, maintenance, and function checks.
5. Assessment with previously analyzed specimens, internal blind samples, or external proficiency-testing samples.
6. Assessment of problem-solving skills.

All six are documented at least twice during the first year the person tests patient specimens in the laboratory and at least annually afterward. A new analyzer or methodology requires training and demonstrated competency before patient results are reported. Proficiency testing can contribute to one procedure and cannot satisfy the complete assessment. Provider-performed microscopy uses five procedures because the instrument-performance procedure does not apply. CLIA does not require formal testing-personnel competency assessment in a waived-only laboratory, although training and correct performance under the manufacturer’s instructions remain required.⁸

A strong assessment uses routine evidence where possible: observe a real run, review actual records, challenge a known problem, and document the assessor, date, test system, all required procedures, findings, remediation, and final determination. A checklist signed without observed evidence does not demonstrate competency.

References

1. Carroll KC, Pfaller MA, Landry ML, McAdam AJ, Karlowsky JA, Patel R, Pritt BS, eds. Manual of Clinical Microbiology. 13th ed. ASM Press; 2023.
2. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 36th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute; 2026. Accessed August 31, 2026.
3. Clinical and Laboratory Standards Institute. Validation, Verification, and Quality Assurance of Automated Hematology Analyzers. 2nd ed. CLSI standard H26. Clinical and Laboratory Standards Institute; 2026. Accessed August 31, 2026.
4. Gulati G, Uppal G, Gong J. Unreliable automated complete blood count results: causes, recognition, and resolution. Ann Lab Med. 2022;42(5):515-530. doi:10.3343/alm.2022.42.5.515.
5. Clinical and Laboratory Standards Institute. One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test. 3rd ed. CLSI standard H47. Clinical and Laboratory Standards Institute; 2023. Accessed August 31, 2026.
6. Bazydlo LAL, Marin MJ, Merrill AE, Man LM, Oladipo OO, Harris NS. ADLM guidance document on coagulation testing in patients using direct oral anticoagulants. J Appl Lab Med. 2025;10(6):1675-1690. doi:10.1093/jalm/jfaf155.
7. Electronic Code of Federal Regulations. 42 CFR part 493: Laboratory Requirements, including §493.1255 and subpart M. Updated through August 27, 2026. Accessed August 31, 2026.
8. Centers for Medicare & Medicaid Services. Assessing Personnel Competency. Revised May 2025. Accessed August 31, 2026.
9. Knowles MS, Holton EF III, Robinson PA, Caraccioli C. The Adult Learner: The Definitive Classic in Adult Education and Human Resource Development. 10th ed. Routledge; 2025.
10. Keohane EM, Preston MM, Mirza KM, Walenga JM, eds. Rodak's Hematology: Clinical Principles and Applications. 7th ed. Elsevier; 2025.